About: NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management. The company has a development and license agreement with Glytech LLC. NRx Pharmaceuticals, Inc. was founded in 2015 and is headquartered in Wilmington, Delaware.
Sector: Healthcare
Industry: Biotechnology
Latest price: $2.66 (-1.12%)
NRXP NASDAQ NRX Pharmaceuticals Inc
NRX Pharmaceuticals Inc share price
Atividade de preço de NRXP
Último preço
$ 2,660
Variação (24h)
-0,03 USD (1,12%)
Volume
877.98K
Volume (média 4 sem.)
-
Abertura
$ 2,70
Variação do dia
$ 2,62 - $ 2,77
Fechamento anterior
$ 2,69
Último negócio
29 Oct, 8:24 pm GMT+0
Atrasado
29 Oct, 8:24 pm GMT+0
NRXP price performance
Atrasado
29 Oct, 8:24 pm GMT+0
quote.marketSignals